Literature DB >> 2939797

Antimicrobial activity of ciprofloxacin against Pseudomonas aeruginosa, Escherichia coli, and Staphylococcus aureus determined by the killing curve method: antibiotic comparisons and synergistic interactions.

L J Chalkley, H J Koornhof.   

Abstract

A derivative of quinolinecarboxylic acid, ciprofloxacin (BAY o 9867) was found to be an effective bactericidal agent against Pseudomonas aeruginosa and Escherichia coli. A bactericidal effect was achieved immediately after the addition of ciprofloxacin. At a concentration of 0.5 micrograms/ml, culture viability was reduced from 5 X 10(5) to about 5 X 10(3) CFU/ml within 15 min, and at 0.1 micrograms/ml, a greater than 10-fold reduction in viability resulted during the first hour after exposure. This bactericidal activity observed during the lag phase in Mueller-Hinton broth was also demonstrated in a nongrowing system. The antibiotics used in comparative studies, i.e., tobramycin, aztreonam, cefotaxime, and azlocillin, did not show this initial bactericidal activity, and ciprofloxacin prevented culture regrowth at lower concentrations. Staphylococcus aureus was not as susceptible to ciprofloxacin; killing occurred at a concentration of 0.5 micrograms/ml only after the onset of exponential growth in the control culture. Synergistic interactions were observed with ciprofloxacin in combination with tobramycin and azlocillin against P. aeruginosa and with cefotaxime and tobramycin against E. coli.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2939797      PMCID: PMC180242          DOI: 10.1128/AAC.28.2.331

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  15 in total

1.  Mechanism of action of nalidixic acid on Escherichia coli. IV. Effects on the stability of cellular constituents.

Authors:  T M Cook; W H Deitz; W A Goss
Journal:  J Bacteriol       Date:  1966-02       Impact factor: 3.490

2.  Investigations into the mechanism of action of the antibacterial agent norfloxacin.

Authors:  G C Crumplin; M Kenwright; T Hirst
Journal:  J Antimicrob Chemother       Date:  1984-05       Impact factor: 5.790

3.  Synergism between aminoglycosides and cephalosporins with antipseudomonal activity: interaction index and killing curve method.

Authors:  H O Hallander; K Dornbusch; L Gezelius; K Jacobson; I Karlsson
Journal:  Antimicrob Agents Chemother       Date:  1982-11       Impact factor: 5.191

Review 4.  DNA gyrase and the supercoiling of DNA.

Authors:  N R Cozzarelli
Journal:  Science       Date:  1980-02-29       Impact factor: 47.728

5.  In vitro antibacterial properties of AT-2266, a new pyridonecarboxylic acid.

Authors:  S Nakamura; A Minami; H Katae; S Inoue; J Yamagishi; Y Takase; M Shimizu
Journal:  Antimicrob Agents Chemother       Date:  1983-05       Impact factor: 5.191

6.  In vitro antibacterial activity of AM-715, a new nalidixic acid analog.

Authors:  A Ito; K Hirai; M Inoue; H Koga; S Suzue; T Irikura; S Mitsuhashi
Journal:  Antimicrob Agents Chemother       Date:  1980-02       Impact factor: 5.191

7.  Tentative interpretive standards for disk diffusion susceptibility testing with norfloxacin (MK-0366, AM-715).

Authors:  D L Shungu; E Weinberg; H H Gadebusch
Journal:  Antimicrob Agents Chemother       Date:  1983-02       Impact factor: 5.191

8.  In vitro activity of Bay 09867, a new quinoline derivative, compared with those of other antimicrobial agents.

Authors:  R Wise; J M Andrews; L J Edwards
Journal:  Antimicrob Agents Chemother       Date:  1983-04       Impact factor: 5.191

9.  Comparative in vitro activity of norfloxacin (MK-0366) and ten other oral antimicrobial agents against urinary bacterial isolates.

Authors:  M Y Khan; R P Gruninger; S M Nelson; R E Klicker
Journal:  Antimicrob Agents Chemother       Date:  1982-05       Impact factor: 5.191

10.  In vitro activity of norfloxacin, a quinolinecarboxylic acid, compared with that of beta-lactams, aminoglycosides, and trimethoprim.

Authors:  H C Neu; P Labthavikul
Journal:  Antimicrob Agents Chemother       Date:  1982-07       Impact factor: 5.191

View more
  49 in total

1.  In vitro activity of ciprofloxacin in combination with ceftazidime, aztreonam, and azlocillin against multiresistant isolates of Pseudomonas aeruginosa.

Authors:  C I Bustamante; R C Wharton; J C Wade
Journal:  Antimicrob Agents Chemother       Date:  1990-09       Impact factor: 5.191

2.  Ofloxacin versus parenteral therapy for chronic osteomyelitis.

Authors:  L O Gentry; G Rodriguez-Gomez
Journal:  Antimicrob Agents Chemother       Date:  1991-03       Impact factor: 5.191

Review 3.  The mode of action of quinolones: the paradox in activity of low and high concentrations and activity in the anaerobic environment.

Authors:  C S Lewin; I Morrissey; J T Smith
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1991-04       Impact factor: 3.267

4.  Effect of clavulanic acid on the activity of ticarcillin against Pseudomonas aeruginosa.

Authors:  F Tausk; C W Stratton
Journal:  Antimicrob Agents Chemother       Date:  1986-10       Impact factor: 5.191

Review 5.  Synergy and antagonism of combinations with quinolones.

Authors:  H C Neu
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1991-04       Impact factor: 3.267

6.  Comparison of the chemistry and diversity of endophytes isolated from wild-harvested and greenhouse-cultivated yerba mansa (Anemopsis californica).

Authors:  Robert O Bussey; Amninder Kaur; Daniel A Todd; Joseph M Egan; Tamam El-Elimat; Tyler N Graf; Huzefa A Raja; Nicholas H Oberlies; Nadja B Cech
Journal:  Phytochem Lett       Date:  2015-03       Impact factor: 1.679

7.  Clinical uses of nalidixic acid analogues: the fluoroquinolones.

Authors:  N Høiby
Journal:  Eur J Clin Microbiol       Date:  1986-04       Impact factor: 3.267

8.  Impact of the dosage schedule on the efficacy of ceftazidime, gentamicin and ciprofloxacin in Klebsiella pneumoniae pneumonia and septicemia in leukopenic rats.

Authors:  R Roosendaal; I A Bakker-Woudenberg; M van den Berghe-van Raffe; J C Vink-van den Berg; B M Michel
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1989-10       Impact factor: 3.267

Review 9.  Synergy and antagonism of fluoroquinolones with other classes of antimicrobial agents.

Authors:  H C Neu
Journal:  Drugs       Date:  1993       Impact factor: 9.546

Review 10.  Clinical pharmacokinetics of ciprofloxacin.

Authors:  K Vance-Bryan; D R Guay; J C Rotschafer
Journal:  Clin Pharmacokinet       Date:  1990-12       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.